Oral Drug May Improve Survival in Men with Metastatic Prostate Cancer (DukeHealth.org)
Nov. 19, 2013
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
New prognostic model predicts survival in advanced prostate cancer (DukeHealth.org)
Oct. 18, 2013
For men with advanced prostate cancer that has progressed after taking hormones and undergoing chemotherapy, getting an accurate prognosis is critical to determine the next steps for treatment.
James Abbruzzese selected Chief of Duke Division of Medical Oncology
Oct. 9, 2013
James Abbruzzese, MD, named Chief of the Duke Division of Medical Oncology and Associate Director for Clinical Research for the Duke Cancer Institute.
Thomas and Janet Kean, Nick Valvano to Receive Duke’s Shingleton Award (DukeHealth.org)
Sept. 26, 2013
The Duke Cancer Institute has named Thomas and Janet Kean of Norwood, N.C., and Nick Valvano of Cary, N.C., president emeritus of The V Foundation for Cancer Research, as the 2013 recipients of the Shingleton Award. The award recognizes the outstanding service and generosity of individuals who are committed to the war against cancer.
Spinal Fusion Material, BMP, Increases Risk of Benign Tumors, Not Cancer (DukeHealth.org)
Sept. 5, 2013
Using a certain bone grafting material for spinal fusion, one of the most common procedures for people with painful vertebral deteriorations, does not appear to result in higher rates of cancer, according to researchers at Duke Medicine.
Doctors should discuss financial concerns of cancer patients (DukeHealth.org)
May 16, 2013
Most cancer patients would like to talk about the cost of their care with their doctors, but often don't because they fear the discussion could compromise the quality of their treatment, researchers at Duke Cancer Institute report.
Cancer studies often lack necessary rigor to answer key questions (DukeHealth.org)
Apr. 29, 2013
Fueled in part by an inclination to speed new treatments to patients, research studies for cancer therapies tend to be smaller and less robust than for other diseases.
Immortality gene mutation identifies brain tumors and other cancers (DukeHealth.org)
Mar. 18, 2013
Newly identified mutations in a gene that makes cells immortal appear to play a pivotal role in three of the most common types of brain tumors, as well as cancers of the liver, tongue and urinary tract, according to research led by Duke Cancer Institute.
Less Invasive Treatment is Associated with Improved Survival in Early Stage Breast Cancer (DukeHealth.org)
Jan. 28, 2013
Patients with early stage breast cancer who are treated with lumpectomy plus radiation have a better chance of survival compared with those who undergo mastectomy, according to Duke Medicine research.
Sickle Cells Show Potential to Attack Aggressive Cancer Tumors (DukeHealth.org)
Jan. 9, 2013
By harnessing the very qualities that make sickle cell disease a lethal blood disorder, a research team led by Duke Medicine and Jenomic, a private cancer research company in Carmel, Calif., has developed a way to deploy the misshapen red blood cells to fight cancer tumors.